Drug Trial Radar · NCT07691970
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,072
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Dec 30, 2032
Study completion Dec 30, 2032
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator, while monitoring safety and tolerability. Study details include: * Participants can transition in ROSY-S once they complete their participation in the parent study and should have received at least one dose of anifrolumab in the parent study. Participants with a treatment gap from parent studies and/or who are on compassionate use are eligible to rollover to ROSY-S study. * The earliest that the Enrolment Visit may occur is at the time of the last visit of the parent study (ie, completion of the parent study's final safety follow-up visit). All required assessments from the safety follow-up visit of the parent study must be completed before the Enrolment Visit of ROSY-S study. * The participants will continue to receive anifrolumab the same way they received it in the parent trial * A participant is considered to have completed the study when they meet one of the discontinuation criteria. * Safety will be monitored throughout the study. Both serious and nonserious AEs will be collected up to 12 weeks after the last dose of anifrolumab and will be reported as part of the primary safety endpoint.
Conditions
- Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Interventions
AnifrolumabCombination product
Anifrolumab pre-filled syringe
AnifrolumabCombination product
Anifrolumab solution for injection in pre-filled pen
AnifrolumabDrug
Anifrolumab concentrate for solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAEs and Non-Serious AEsTime frame: From first dose administered and until 12 weeks after the last dose of Anifrolumab
Locations
166 sites in 35 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona · Not yet recruiting
Research Site
Irvine, California · Not yet recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
San Francisco, California · Not yet recruiting
Research Site
Boca Raton, Florida · Recruiting
Research Site
Fort Lauderdale, Florida · Recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Indianapolis, Indiana · Not yet recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Ann Arbor, Michigan · Not yet recruiting
Research Site
Rochester, Minnesota · Not yet recruiting
Research Site
Omaha, Nebraska · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
Charlotte, North Carolina · Recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Columbus, Ohio · Not yet recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
Charleston, South Carolina · Not yet recruiting
Research Site
Dallas, Texas · Not yet recruiting
Research Site
Roanoke, Virginia · Not yet recruiting
Research Site
Quilmes, Argentina · Not yet recruiting
Research Site
San Miguel, Argentina · Not yet recruiting
Research Site
Melbourne, Australia · Not yet recruiting
Research Site
Mitcham, Australia · Not yet recruiting
Research Site
Westmead, Australia · Not yet recruiting
Research Site
Graz, Austria · Not yet recruiting
Research Site
Graz, Austria · Not yet recruiting
Research Site
Linz, Austria · Not yet recruiting
Research Site
Vienna, Austria · Not yet recruiting
Research Site
Ghent, Belgium · Not yet recruiting
Research Site
Leuven, Belgium · Not yet recruiting
Research Site
Belo Horizonte, Brazil · Not yet recruiting
Research Site
Porto Alegre, Brazil · Not yet recruiting
Research Site
Rio de Janeiro, Brazil · Not yet recruiting
Research Site
Salvador, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
Haskovo, Bulgaria · Not yet recruiting
Research Site
Plovdiv, Bulgaria · Not yet recruiting
Research Site
Sofia, Bulgaria · Not yet recruiting
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.